Abemaciclib metabolite M2-d6

• UNSPSC Description:

  Abemaciclib metabolite M2-d6 is the deuterium labeled Abemaciclib metabolite M2. Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50s in the range of 1-3 nM. Anti-cancer activity[1][2].

• Target Antigen:

  CDK

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Purity:

  99.25

• Solubility:

  DMSO : 2.12 mg/mL (ultrasonic)

• Smiles:

  CC1=NC2=C(C=C(C3=C(C=NC(NC4=CC=C(C=N4)CN5CCNCC5)=N3)F)C=C2N1C(C([2H])([2H])[2H])C([2H])([2H])[2H])F

• Molecular Weight:

  484.58

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Teresa Burke, et al. Abstract 2830: The major human metabolites of abemaciclib are inhibitors of CDK4 and CDK6. Cancer Research. July 2016, 76 (14).

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, sealed storage, away from moisture and light)

• Clinical Information:

  No Development Reported